Zhongmou Therapeutics
Clinical trials sponsored by Zhongmou Therapeutics, explained in plain language.
-
Gene therapy injection aims to halt vision loss in dry AMD
Disease control Not yet recruitingThis early-phase trial tests a gene therapy called AGX-08 for geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. About 24 adults aged 50 and older will receive a single injection into one eye, with different dose levels being tested…
Phase: EARLY_PHASE1 • Sponsor: Zhongmou Therapeutics • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
New eye injection aims to slow vision loss in rare disease
Disease control Not yet recruitingThis early-stage trial tests a single injection of ZM-02 in 21 people aged 6 to 60 with advanced retinitis pigmentosa, a genetic eye disease that causes vision loss. The study checks if the treatment is safe and whether it can improve vision and quality of life compared to a sham…
Phase: PHASE1, PHASE2 • Sponsor: Zhongmou Therapeutics • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC